Navigation Links
Phase II Medical Manufacturing Selects IQMS for ERP Solution

EnterpriseIQ Supports Device Manufacturer's Continued Growth and Compliance

PASO ROBLES, Calif., Feb. 5 /PRNewswire/ -- IQMS, a leader in the design and development of Enterprise Resource Planning (ERP) software, has been selected by Phase II Medical Manufacturing for its comprehensive ERP software, EnterpriseIQ. As Phase II continues to excel in the medical device manufacturing industry, so does the level of visibility needed to manage the company's growth. Phase II is committed to continual quality and compliance as an FDA-approved, and ISO 9001:2000 and ISO 13485:2003 certified manufacturer. EnterpriseIQ supports this effort by enabling the company to best manage time-to-market and traceability, and sustain continued growth and conformance.

"Rapid expansion was taxing our spread-sheet based system," says Adam Prime, president of Phase II. "To remain competitive, we needed a robust ERP system that could grow with us and cost-effectively manage our quality and compliance issues. EnterpriseIQ was the perfect fit. With modules like Quality Medical, RealTime Machine Monitoring, and Customer Relationship Management, we now have more control over our core business data, and because EnterpriseIQ is scalable we are well prepared for long-term growth and success."

The Quality Medical and Device History Record (DHR) modules are included in EnterpriseIQ to address the unique needs of medical manufacturers. These modules facilitate better internal communication and collaboration while ensuring quality standards compliance with capabilities such as: adherence to TS13485 and ISO 9001 standards, and CFR and FDA requirements; up-front risk assessment; electronic signature and document control; complete audit trail of manufacturing processes; comprehensive Corrective Action/Preventive Action (CAPA); and non-conforming product review and tracking. With EnterpriseIQ, medical device manufacturers can streamline operations and product development to gain a stronger competitive advantage.

"Medical device manufacturers operate in one of the world's most highly regulated industries," says Randy Flamm, president and founder of IQMS. "IQMS is committed to helping manufacturers like Phase II succeed in their ever-changing and complex industry. We've tailored EnterpriseIQ specifically to make their jobs easier. That's why so many Class 1, 2 and 3 device manufacturers rely on IQMS as their single-source ERP provider. We are thrilled Phase II has joined them, and we look forward to helping Phase II accelerate their success for many years to come."

About Phase II

Founded in 1995 to serve the single-use medical product and device industry, Phase II Medical Manufacturing now provides design, development, manufacturing, packaging, shipping, and sterilization services to its customers. FDA registration, Canadian licensing, and ISO 9001:2000 and ISO 13485:2003 certification are maintained to ensure that current U.S. and international standards are satisfied. Phase II works closely with clients on a regular basis to ensure all devices meet or exceed specifications, and its commitment and dedication to customers is unmatched in the industry.

About IQMS

Since 1989, IQMS has been a pioneer in the design and development of ERP software for repetitive, process and discrete manufacturing industries. Today, IQMS provides leading real-time manufacturing, accounting, machine monitoring, quality control, supply chain, CRM and eBusiness solutions to the automotive, medical, packaging, consumer goods and other manufacturing markets. The only complete, single-source enterprise software solution, EnterpriseIQ offers real-time front office, accounting, manufacturing and supply chain management in a single database. With offices across North America, Europe and Asia, IQMS serves manufacturers around the world. Visit IQMS online at

IQMS and EnterpriseIQ are trademarks of IQMS. All other brand and product names are the trademarks of their respective companies.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
3. Mannatech Launches Phase One of New Sales and Training Tools
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Manic phase of bipolar disorder benefits from breast cancer medication
6. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: